PPT-Peginterferon

Author : tawny-fly | Published Date : 2017-12-16

alfa 2b RBV vs Peginterferon alfa 2a RBV IDEAL STUDY Phase 3 Treatment Naïve Treatment Naïve Chronic HCV McHutchison JG et al N Engl J Med 200936158093

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Peginterferon" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Peginterferon: Transcript

alfa 2b RBV vs Peginterferon alfa 2a RBV IDEAL STUDY Phase 3 Treatment Naïve Treatment Naïve Chronic HCV McHutchison JG et al N Engl J Med 200936158093 . ELECTRON (Overview): 6 parts, 22 arms. Phase . 2. Treatment. Naïve and Treatment . Experienced. Source: . Gilead Sciences, . Inc. Sofosbuvir. Summary of ELECTRON Trials Design (1 of 2). Part 1 . - . for Patients with Prior Failure to PEG + RIB. PROVIDE. Phase . 3. Treatment. . Experienced. Vierling. JM, . et al. . J . Hepatol. . 2013;Dec 19 [. Epub. ahead of print].. Source: . Vierling. . JM, et al. J . Genotype . 1 . (. Viral . Relapsers. ). PROMISE . Trial. Phase . 3. Treatment. . Experienced. Forns. X. , . et al. . Gastroenterology. 2014;146:1669-79.e3.. Source: . Forns. X. , et al. Gastroenterology. 2014;146:1669-79.e3.. Treatment –Experienced Genotype . 1 . ASPIRE Trial. Phase . 3. Treatment. . Experienced. Z. euzem. S. , . et al. . Gastroenterol. . 2014;146:430-41.. Source: . Zeuzem. S. , et al. . Gastroenterol. versus . Telaprevir. . with PR in GT1 . ATTAIN Trial. Phase . 3. Treatment. . Experienced. Reddy KR. , . et al. . Lancet Infect Dis. 2015;15:27-35.. Source: Reddy KR. , et al. Lancet Infect Dis. 2015;15:27-35.. versus. . Interferon alfa-2b + Ribavirin . Phase 3. Treatment. . Naïve, Chronic HCV. Manns. . MP, et. al. Lancet. 2001;358:958-65. Peginterferon alfa-2b + Ribavirin . versus . Interferon alfa-2b + Ribavirin . with PEG + RBV in Genotype 1. SPRINT. -1. Phase . 2. Treatment. . Naïve. Kwo. PY, et al. Lancet. 2010;376:705-16.. Source: . Kwo PY, et al. Lancet. 2010;376:705-16. .. Boceprevir . for Treatment-Naïve HCV Genotype 1. SPRINT-2. Phase 3, Treatment . Naive. Treatment. . Naïve. Source: . Poordad F, . et al. . N Engl J Med. 2011;364:1195-206.. Boceprevir . for Treatment-Naïve HCV Genotype 1. SPRINT. -2 Trial: Study Design. Flat versus Weight-Based Ribavirin Dosing. Phase . 3. Treatment. . Naïve, Chronic HCV. Jacobson IM, et. al. Hepatology. 2007;46:971-81.. *Weight-based . ribavirin. dosing: < 65 kg: 800 mg/. d. . or 3 . LONESTAR-2. Phase 2. Treatment. . Experienced. Lawitz. . E, et al. . Hepatology. . 2015:61:769-75.. Source: . Lawitz. E, et al. . Hepatology. . . 2015:61:769-75.. Sofosbuvir + . PEG + RBV . RBV . versus. Interferon alfa. -. 2a + RBV . ACTG 5071. Phase . 2. Treatment. . Naïve, Chronic HCV and HIV. Chung RT, . et. al. N . Engl. J Med. . 2004;351:451-9. . PEG alfa. -2a . + . RBV . versus. versus. Interferon alfa-2b + Ribavirin. Phase 3. Treatment. . Naïve, Chronic HCV. Fried MW, . et al. N . Engl. J Med. . 2002;347:975-. 8. 2. .. Peginterferon +/- Ribavirin versus Interferon + . Ribavirin. Chronic hepatitis C virus (HCV) infection is one of the most common chronic liver disease and accounts for 8000 to 13,000 deaths each year. . The majority of liver transplants performed in the United States are for chronic HCV. . ID . : . DB00008 . Protein average . weight : . 60000.0000. . Half life : . Terminal half life is 80 hours (range 50 to 140 hours). . . Description. :. . Human interferon 2a, is a covalent conjugate of recombinant alfa-2a interferon with a single branched .

Download Document

Here is the link to download the presentation.
"Peginterferon"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.